The global radiosurgery and radiotherapy robots market is set to enjoy a valuation of US$ 5.8 billion in 2022. Worldwide sales of radiosurgery and radiotherapy robots are predicted to increase at a steady CAGR of 4.6% to reach a market valuation of US$ 7.1 billion by the end of 2026.
The employment of robots in radiotherapy is being driven by the high requirement for precise and secure delivery of focused high medication doses to the targeted area. The main benefits of radiosurgery and radiotherapy robotic systems are their adaptability in a beam setup and their capacity to account for targeted motion.
Top companies in radiosurgery robots are investing heavily to gain a competitive edge over one another and progress in this market landscape. The market for radiosurgery and radiotherapy robots is expanding into new regions and introducing advanced products at the same time.
New product approvals and launches are both important for market players to enhance their stance as well as drive revenue generation in the market.
- The U.S. Food and Drug Administration approved the novel non-invasive stereotactic radiation system that is used to treat breast cancer, in December 2017, manufactured by the company Xcision Medical Systems, LLC.
- As part of its commitment to provide painless, precise, and non-invasive radiation treatment to thousands of patients being treated for incurable malignant and non-cancerous tumours, Artemis Hospitals introduced North India’s first M6 Cyberknife Radiosurgery technology in August 2017.
- Accuray, Inc.
- Best Theratronics Ltd.
- BrainLab AG
- Elekta AB
- Huiheng Medical, Inc.
- Masep Medical Science & Technology Development (Shenzhen) Co., Ltd.
- Neusoft Medical Systems Co., Ltd.
Key Takeaways from Market Study
- The global radiosurgery and radiotherapy robots market is to reach a valuation of US$ 5.8 billion by 2026.
- Demand for radiosurgery and radiotherapy robots is expected to increase at a CAGR of 4.6% from 2022 to 2026.
- Radiosurgery and radiotherapy robot sales growth is aided by hospitals treating patients with tumours of cancerous or non-cancer type.
- North America is handsomely leading the global radiosurgery and radiotherapy robots market.
According to Fact.MR’s analyst, “the manner that radiosurgery and radiotherapy therapies are reimbursed varies greatly depending on the local government. However, the improved environment is motivating more patients to choose these therapies, which is expected to boost market expansion”.
Many companies are emphasizing organic growth strategies, including new product releases, product approvals, and other factors such as patents and promotional events.
One of the growth strategies seen in the market is mergers and acquisitions, along with partnerships and collaborations. Market participants now have the opportunity to expand their businesses due to activities such as the creation of new products and the improvement of existing ones.
- Digital Surgery, a pioneer in surgical artificial intelligence, data, and analytics, was purchased by Medtronic (U.S.) in February 2020. As a result, the portfolio and platform for robot-assisted surgery at Medtronic have expanded.
For More Insights of Fact.MR : https://www.globenewswire.com/en/news-release/2022/08/01/2489804/0/en/High-Usage-of-Radiosurgery-and-Radiotherapy-Robots-in-Hospitals-Due-to-Increasing-Cases-of-Cancerous-Non-cancerous-Tumours-Fact-MR-Study.html